Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Colorcon
Dow
Boehringer Ingelheim
Harvard Business School

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Litigation Details for ELI LILLY AND COMPANY v. TEVA PHARMACEUTICALS USA, INC. (S.D. Ind. 2006)

See Plans and Pricing

« Back to Dashboard

ELI LILLY AND COMPANY v. TEVA PHARMACEUTICALS USA, INC. (S.D. Ind. 2006)

Docket   Start Trial Date Filed 2006-06-29
Court District Court, S.D. Indiana Date Terminated 2009-09-23
Cause 35:271 Patent Infringement Assigned To Sarah Evans Barker
Jury Demand None Referred To Judge Jane Magnus-Stinson
Parties ELI LILLY AND COMPANY; TEVA PHARMACEUTICALS USA, INC.
Patents 4,418,068; 5,393,763; 5,457,117; 5,478,847; 5,811,120; 5,972,383; 6,458,811; 6,797,719; 6,894,064; 6,906,086; RE38,968; RE39,049; RE39,050
Attorneys Adam G. Kelly; Alissa Keely Lipton; Amy E. Purcell; Charles Edmund Lipsey; Daniel W. Celander; David S. Forman; Edward H. Rice; James Dimos; Jan M. Carroll; Jennifer H. Roscetti; Joel E. Tragesser; Jordan A. Sigale; Julie P. Samuels; L. Scott Burwell; Laura P. Masurovsky; Marina N. Saito; Mark Jeremy Feldstein; Michael J. Freno; Robert Francis McCauley; Steven J. Lee; Steven M. Lubezny; Terri L. Bruksch; Walter E. Hanley , Jr.; William Barrett Raich
Firms Barnes & Thornburg LLP; Finnegan Henderson Farabow Garrett & Dunner; Finnegan Henderson Farabow Garrett & Dunner LLP; Finnegan Henderson Farabow Garrett and Dunner; Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.; Kenyon & Kenyon LLP; Kenyon and Kenyon; Loeb & Loeb LLP
Link to Docket External link to docket
Small Molecule Drugs cited in ELI LILLY AND COMPANY v. TEVA PHARMACEUTICALS USA, INC.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for ELI LILLY AND COMPANY v. TEVA PHARMACEUTICALS USA, INC. (S.D. Ind. 2006)

Date Filed Document No. Description Snippet Link To Document
2006-06-29 1 Complaint Exhibit C-reissued patent No. US RE39,049 E# (4) Exhibit D-patent No. US 6,906,086 B2)(DH, ) 29 June…(1) Exhibit A-reissued patent No. US RE39,050 E# (2) Exhibit B-reissued patent No. US RE38,968 E# (3) …23 September 2009 1:06-cv-01017-SEB-JMS Patent None District Court, S.D. Indiana External link to document
2007-08-31 126 SEALED Document US Patent No. 6,458,811 B1# (2) Exhibit A-2 US Patent No. 6,458,811 B1# (3) Exhibit A-3 US Patent No.…No. 6,458,811 B1# (4) Exhibit A-4 US Patent No. 6,458,811 B1# (5) Exhibit B - Excerpts from Deposition …23 September 2009 1:06-cv-01017-SEB-JMS Patent None District Court, S.D. Indiana External link to document
2008-02-15 153 Exhibit EXHIBIT re [151] SEALED Document A - U.S. Patent No. 6,458,811 B1 by TEVA PHARMACEUTICALS USA, INC.. (…Excerpt from Prosecution History of U.S. Patent No. 6,458,811 B1 (4/9/02 Response to Office Action), #…Excerpt from Prosecution History of U.S. Patent No. 6,458,811 B1 (6/3/02 Notice of Allowance), # (13) … # (1) Exhibit B - U.S. Patent No. 6,797,719 B2, # (2) Exhibit C - U.S. Patent No. 6,894,064 B2, # (3)…23 September 2009 1:06-cv-01017-SEB-JMS Patent None District Court, S.D. Indiana External link to document
2008-06-11 181 Entry 086 patent); U.S. Patent No. 6,458,811 (the ‘811 patent); U.S. Patent No. 6,797,719 (the ‘719 patent); … The patents under dispute are: U.S. Patent No. RE39,050 (the ‘050 patent); U.S. Patent No. RE38,…RE38,968 (the ‘968 patent); U.S. Patent No. RE39,049 (the ‘049 patent); U.S. Patent No. 6,906,086 (the ‘086…; and U.S. Patent No. 6,894,064 (the ‘064 patent). For present purposes, all the disputed terms…appear in the ‘811, ‘719, and ‘064 patents (the “particle size patents”). External link to document
2008-10-24 308 SEALED Document Vitae, # 2 Exhibit B to Declaration - U.S. Patent 6,458,811, # 3 Exhibit C to Declaration - Particle-size…23 September 2009 1:06-cv-01017-SEB-JMS Patent None District Court, S.D. Indiana External link to document
2008-10-24 309 SEALED Document T14615), # 23 Exhibit 23 to Expert Report - U.S. 4,418,068 (Ex 180), # 24 Exhibit 24 to Expert Report - U.S…Report - October 10, 2001 Office Action at 2-3 (811 patent), # 51 Exhibit 32 to Expert Report - April 9, 2002… 2002 Response to Office Action at 9 (811 patent), # 52 Exhibit 33 to Expert Report - May 29, 2002 Notice…Notice of Allowability at 2 (811 patent), # 53 Exhibit 34 to Expert Report - April 28, 1994 Office Action…23 September 2009 1:06-cv-01017-SEB-JMS Patent None District Court, S.D. Indiana External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Dow
McKinsey
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.